Mission Statement

PrimerGen is a startup biopharmaceutical company operating at the interface of small molecule drug discovery and the biologics space. Our mission is to develop and accelerate treatments for presently unmet medical needs in the fields of kidney and lung disease. Some of our ongoing projects are described below.

Lung Disease

COVID-19

Corona Virus Disease 2019 caused by the SARS-CoV-2 virus. We are currently pursuing the development of an antiviral treatment for COVID-19. We are evaluating whether existing FDA-approved medications may be repurposed for the treatment of COVID-19.
To learn more about our strategy for COVID-19, contact us at: geral@primergen.group

LAM

Lymphangioleiomyomatosis, a rare progressive genetic disease of the lung that predominantly affects women of reproductive age. There is currently no cure for LAM. We are actively pursing the development of an anti-proliferative agent for the treatment of LAM disease.
To learn more about our strategy for LAM, contact us at: geral@primergen.group

Kidney Disease

TSC

Tuberous Sclerosis Complex is a rare genetic disorder characterized by the development of benign tumours in various organs including the kidneys. TSC patients often develop highly-vascularized tumours known as angiomyolipomas. We are interested in the development of novel treatments that reduce tumor formation and improve overall kidney function.
To learn more about our strategy for TSC, contact us at: geral@primergen.group

ADPKD

Autosomal Dominant Polycystic Kidney Disease is genetic disorder characterized by growth of numerous cysts in the kidneys. ADPKD is among the most common monogenic genetic disorders. Symptoms progress steadily throughout life and there is currently no effective treatment against this disease.
To learn more about our strategy for ADPKD, click the link below: